In Fight Against Alzheimer’s, $100 Million Genentech (RHHBY) Trial in Colombia May Be Ground Zero
COLOMBIA -- A $100 million Genentech (RHHBY) study on Alzheimer’s treatment is focusing on members of a Colombian family who may carry a rare gene that leads to early onset dementia research by age 45, the Wall Street Journal reported this morning. I ...